Trials / Completed
CompletedNCT00298623
XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 222 (actual)
- Sponsor
- XenoPort, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XP13512 (GSK1838262) | |
| OTHER | placebo |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2007-02-01
- Completion
- 2007-02-01
- First posted
- 2006-03-02
- Last updated
- 2013-05-14
Source: ClinicalTrials.gov record NCT00298623. Inclusion in this directory is not an endorsement.